case reports aspiration glp-1 receptor agonist anesthesia 2023 Glucagon-Like Peptide-1 (GLP-1) Agonists: Risk of during Filipino American Nurse Anesthesiology Society

Traditionally, both single and combination FDA-approved drugs for obesity have shown moderate, but clinically-important, weight losses (mean weight loss of 3%9% greater than placebo at ~1 year of therapy) (4) (Figure 1)

C.CardosoS

With thoughtful nutrition, close monitoring, and coordination with your healthcare provider, mothers can continue breastfeeding while using tirzepatide

And I'll say, reading the book doing all the sort of thinking and research about GLP-1s and then reading the book kind of felt like reading a book from another era

PIONEER 9 and PIONEER 10 are trials that enrolled Japanese participants with T2DM to meet regulatory requirements in Japan

Two patients who spaced doses of semaglutide or tirzepatide maintained a large proportion of their prior weight loss, illustrating feasibility in real-world settings